Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-21-009545.pdf
0001558370-21-009545.rtf
0001558370-21-009545.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-21-009606.pdf
0001558370-21-009606.rtf
0001558370-21-009606.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-21-009477.pdf
0001558370-21-009477.rtf
0001558370-21-009477.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
CT ORDER

CT ORDER

 View HTML
9999999997-21-003887.pdf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-007172.pdf
0001179110-21-007172.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-21-082076.pdf
0001104659-21-082076.rtf
0001104659-21-082076.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006417.pdf
0001179110-21-006417.rtf
0001179110-21-006417.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006416.pdf
0001179110-21-006416.rtf
0001179110-21-006416.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006415.pdf
0001179110-21-006415.rtf
0001179110-21-006415.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006414.pdf
0001179110-21-006414.rtf
0001179110-21-006414.xls